These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 27672277

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
    Sato S, Genda T, Ichida T, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Ishikawa S, Kikuchi T, Mori M, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S.
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
    Mori M, Genda T, Ichida T, Murata A, Kamei M, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Ishikawa S, Kikuchi T, Shimada Y, Hirano K, Iijima K, Sugimoto K, Wada R, Nagahara A, Watanabe S.
    Hepatol Res; 2017 Mar; 47(3):E85-E93. PubMed ID: 27084455
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
    Wang YY, Qi LN, Zhong JH, Qin HG, Ye JZ, Lu SD, Ma L, Xiang BD, Li LQ, You XM.
    Sci Rep; 2017 Feb 09; 7():42199. PubMed ID: 28181486
    [Abstract] [Full Text] [Related]

  • 8. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu H, Yu H, Lu XY, Xian ZH, Liu YK, Cong WM, Wu MC.
    J Hepatol; 2013 Sep 09; 59(3):510-7. PubMed ID: 23665285
    [Abstract] [Full Text] [Related]

  • 9. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
    Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, Morio K, Kan H, Fujino H, Kobayashi T, Fukuhara T, Masaki K, Ono A, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Kawakami Y, Ochi H, Chayama K, Hiroshima Liver Study Group.
    J Gastroenterol Hepatol; 2016 May 09; 31(5):1009-15. PubMed ID: 26584407
    [Abstract] [Full Text] [Related]

  • 10. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
    Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, Narita Y, Ishikawa S, Kikuchi T, Mori M, Hirano K, Iijima K, Wada R, Ichida T.
    Int J Mol Sci; 2014 Apr 17; 15(4):6556-68. PubMed ID: 24747592
    [Abstract] [Full Text] [Related]

  • 11. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
    Ogata F, Kobayashi M, Akuta N, Osawa M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.
    Oncology; 2017 Apr 17; 93(2):92-98. PubMed ID: 28448999
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
    Han C, Gao L, Zhao L, Sheng Q, Zhang C, An Z, Xia T, Ding Y, Wang J, Bai H, Dou X.
    Med Sci Monit; 2018 Oct 17; 24():7414-7423. PubMed ID: 30328412
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
    Ha SY, Song DH, Lee JJ, Lee HW, Cho SY, Park CK.
    Gut Liver; 2014 Nov 17; 8(6):648-54. PubMed ID: 25287169
    [Abstract] [Full Text] [Related]

  • 19. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
    Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, Auer T, Gamerith G, Loeffler-Ragg J.
    Liver Int; 2011 Jul 17; 31(6):810-6. PubMed ID: 21645211
    [Abstract] [Full Text] [Related]

  • 20. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, Lu SN.
    Liver Int; 2016 Dec 17; 36(12):1793-1799. PubMed ID: 27254286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.